Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

The device for endotoxic septic shock was first approved in Europe more than 20 years ago, in 1994, by Toray Industries.

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Newron has randomised the first participants in its ENIGMA-TRS 1 Phase III programme of evenamide for treatment-resistant ...

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

The FDA has given the green light for Tiziana Life Sciences’ IND to advance its Phase IIa study of intranasal foralumab for MSA.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome treatment.

NHS England is set to offer expedited access to the trial for BioNTech’s new cancer vaccine, BNT113-01, for individuals with advanced head and neck cancers.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.